Pharmacy Practice News Corporate Profiles 2012

Special Advertising Section

American Health Packaging

Grifols

PharMEDium Services

CutisPharma, Inc.

ICU Medical, Inc.

Pharmacy Practice News

Medi-Dose, Inc./EPS, Inc.

The profiles in this section were submitted by the advertisers.

American Health Packaging Prepackaged Unit Dose Provides Many Benefits for Health Systems

AT A GLANCE Address American Health Packaging 2550-A John Glenn Ave. Columbus, OH 43217 Phone: (800) 707-4621 Fax: ( 614) 492-0448 Web site: www.americanhealthpackaging.com

Products Bar-coded unit dose generics, unit-of-use bottles, bar-coded pouches, compliance prompting packaging

Vice President/ General Manager Rick Knight

Vice President, Sales and Marketing Brian McMillan

Patient safety is a critical issue for health systems. As a result, many health systems seek bar-coded product to dispense to patients. Bar-coded products used in conjunction with bar code medication administration (BCMA) systems, automate the “five rights.” American Health Packaging supports this health systems’ priority with its growing line of prepackaged unit-dose products.

There are many benefits to American Health Packaging prepackaged unit-dose products: Safety. Companies that specialize in pharmaceutical packaging are highly regulated and scrutinized by the FDA. Good Manufacturing Practices (cGMP) compliance ensures that products are packaged in a regulated and safe environment. Packaging professionals are adept at ensuring the product’s lot number, National Drug Code and expiration date are recorded correctly and legibly.

Pharmacy efficiency. Pharmacies are concerned with the timely processing of orders to supply the proper medications to patients quickly as possible. Adding a multitude of steps to package and check commercially available products in-house not only slows down this process, it also takes those clinicians away from their core competency—patient care.

Liability management. Packaging products within health system pharmacies can be met with various distractions in terms of quality systems and process controls. Errors that arise can place the liability on the hospital, as well as the caregivers themselves. Mitigation of risk is key. Purchasing medications from a highly regulated, cGMP compliant company such as AHP shifts some of the burden of responsibility from the health system.

Cost savings. In addition to shifting the potential costs of errors, health systems that choose to package on-site must consider other direct costs such as establishing the Find Us at the

Intersection of Patient Safety and Pharmacy Efficiency!

20

Corporate Profile 2012

packaging infrastructure as well as paying the highly trained professional staff to perform, manage and support non-core work.

Safety in Every Dose Bar-coded to the dose level, our unit dose line has grown substantially in the last couple of years. The line now contains over 350 SKUs. And, nearly a third are exclusives— industry only available from American Health Packaging in a unit dose bar coded package format.

American Health Packaging’s products support many therapeutic classes. Recent product Our bar-coded unit dose products support introductions include health systems’ patient safety efforts.

Atorvastatin Calcium Clopidogrel tablets, Quetiapine tablets, Fumarate tablets, Olanzapine and Ziprasidone HCl tablets.

About American Health Packaging American Health Packaging is a subsidiary of AmerisourceBergen. Our manufacturing facility is registered with the FDA and fully adheres to current cGMP. Industry veterans with nearly 100 years of collective experience lead the quality and manufacturing departments. American Health Packaging is licensed by the Drug Enforcement Administration to package Schedule II to V controlled substances.

Many of our UD products are industry exclusives—only available from AHP.

Special Advertising Section Pharmacy Practice News

CutisPharma, Inc. CutisPharma, Inc., brings innovation and value to the prescription-compounding sector of hospital and healthsystem pharmacies.

Unit-of-Use kits simplify the entire process—they quicken preparation, enhance patient safety, and facilitate reimbursements. What typically takes compounders up to fifteen minutes to do now takes just one minute or less. All kits are bar-coded and facilitate pharmacists’ conformance to USP Chapter <795> standards.

wash BLM 4 oz and FIRST® - Mouthwash BLM 6 oz compounding kits. These products expand the FIRST® Magic Mouthwash line for CutisPharma.

The product line already includes FIRST® - MouthAddress wash BLM 8 oz, Duke’s Mouthwash, Mary’s Mouth68 Cummings Park wash and BXN Mouthwash. The active ingredients Woburn, MA 01801 in FIRST® - Mouthwash BLM are comparable to Contact: Jim Nagle, Vice those found in the most routinely prepared formuPresident–Business Development lation of Magic Mouthwash containing Benadryl®, Phone: (781) 935-8141 ext. 120 lidocaine and Maalox®. The kits are made for one E-mail: JNagle@cutispharma.com patient and include pre-weighed Web site: www.cutispharma.com powders and a pre-measured sus® pension. With FIRST - Mouthwash Products Kits, the pharmacist needs only to FIRST® - Omeprazole Suspension add the powders to the liquid sus3, 5, 10 oz sizes pension, shake, and then dispense FIRST® - Lansoprazole Suspension to the patient.

3, 5, 10 oz sizes “Pharmacies have told CutisFIRST® - Mouthwash BLM 4, 6, Pharma, and our research has 8 oz sizes indicated that there are just as ® The FIRST® Magic Mouthwash line FIRST - BXN Mouthwash many 4 oz and 6 oz prescriptions ® contains FIRST® _ Mouthwash BLM 4, FIRST - Dukes Mouthwash for ‘Magic Mouthwash’ containing 6 and 8 oz sizes, BXN, Duke’s and ® FIRST - Mary’s Mouthwash ® ® Benadryl , lidocaine and Maalox Mary’s versions.

FIRST® 10% Hydrocortisone in as there are for 8 oz prescriptions.

Ultrasound Gel Compounding Kit By launching FIRST® - Mouthwash BLM 4 oz and 6 oz, pharmacists now have greater flexibility in filling FIRST® ‘Magic Mouthwash’ prescriptions,” said Dr. Muni. “The Company now has a wide range of FIRST® ‘Magic Mouthwash’ formulations to choose from, particularly for the most commonly prescribed and used.”

FIRST® products save dispensing time, and can be by the pharmacist while the patient compounded Now available: FIRST® – Omeprazole waits, increasing customer satisfaction. Using FIRST® and FIRST® – Lansoprazole Suspension Unit-of-Use CompoundMouthwash kits, the pharmacist can compound a ing Kits in 3, 5 and 10 oz sizes. prescription faster than those prepared in the conventional way.

Greater efficiencies in the compounding process bring multiple financial and clinical gains to hospital and health-system pharmacies. By using premeasured, pre-weighed unit-of-use prescription compounding kits, pharmacies and nurses save significant staff time in preparation, help lower the total costs of compounding, facilitate reimbursements, and refine their just-in-time inventories to ensure ingredients are on hand when needed and ready to use over longer periods of shelf life.

Clinically, the packaged reagents help deliver consistent accuracy of the compound admixtures and quicken medication delivery to patients, if compounded according to instructions, because they’re easier and quicker to use than the typical laborious processes. These benefits in turn may lead to better patient health outcomes.

Industry-wide savings can be vast. FDA estimates 30 million hospital-outpatient and retail compounding prescriptions are filled per year.

Inpatient figures are also significant, yet harder to pinpoint because they lack a single NDC number, says Jim Nagle, Vice President-Business Development, CutisPharma, Woburn, MA. Every FIRST® Unit-of-Use kit end-use container has a bar code.

The NDC number imprinted on each end-use container in every CutisPharma FIRST® Unit-ofUse kit facilitates third-party reimbursement for hospitals and health systems. The single NDC number for the entire kit may also improve patient safety, because of minimized dispensing errors, suiting the growing number of inpatient and outpatient pharmacies that barcode prescriptions from point of dispensing to point of care.

CutisPharma Expands Product Line with new Oral Suspension Prescription Compounding Kits CutisPharma, Inc., introduced in January 2012, FIRST® - Omeprazole and FIRST® - Lansoprazole Unit-of-Use oral suspension compounding kits. These new kits will help pharmacists dispense these compounded prescriptions containing widely used proton pump inhibitors (PPIs). Traditionally, compounded omeprazole and lansoprazole oral suspensions can take up to several hours to prepare and are quite unpleasant to the taste. With FIRST® - Omeprazole and FIRST® - Lansoprazole, pharmacists need only add the liquid suspension to the powder, shake, and then within minutes can dispense to the patient with improved flavoring.

“We invested a lot of time to develop these new suspension kits.

The results are a pleasant-tasting strawberry-flavored medication with adequate stability once compounded,” said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. “These products offer another advantage for hospital use; since the suspensions are made using powders, and not pellets, our new compounded suspensions should flow more easily through nasogastric (NG) tubes, with minimal clogging compared to current practice. Also, our three different sizes of packaging, 3 oz, 5 oz and 10 oz, provide considerable prescribing flexibility.”

AT A GLANCE

10% Hydrocortisone in Ultrasound Gel Compounding Kit Primarily prescribed for physical therapy patients, the FIRST® 10% Hydrocortisone in Ultrasound Gel Compounding Kit made for a single patient, contains 6 grams of micronized hydrocortisone USP in a 24-gram suspension with propylene glycol USP and simethicone USP. It also includes 36 grams of ultrasound gel for topical use. The kit has a two-year shelf life prior to compounding.

There are approximately 350,000 10% Hydrocortisone in Ultrasound Gel prescriptions written annually. CutisPharma cost comparison shows that FIRST® 10% Hydrocortisone unit-of-use kit can yield a profit of over $9 for a compounding pharmacy vs. a loss of over $16 when the admixture is compounded conventionally. Also, preparation time is cut to two minutes from well over fifteen minutes.

Growing Portfolio Serves Compounding Needs The CutisPharma portfolio is growing to meet pharmacy’s increasing reliance on compounding—and its need for efficiencies, safety and convenience.

CutisPharma now has twenty proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, six Magic Mouthwash kits, three omeprazole suspension kits and three lansoprazole suspension kits. Several more compounding kits are in the planning stages. The use of FIRST® Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>.

CutisPharma Launches New Prescription Mouthwash Kits, Expanding Product Line CutisPharma, Inc., announced the introduction of FIRST® - Mouth-

Special Advertising Section Pharmacy Practice News

Corporate Profile 2012

21

Grifols AT A GLANCE Address 2410 Lillyvale Ave. Los Angeles, CA 90032 Phone: (888) GRIFOLS (474-3657) Web site: www.grifols.com

Divisions Bioscience: Specializes in the research, development, production and commercialization of high-quality plasma therapies.

Hospital: Specializes in operational solutions for compounding areas in pharmacy.

Diagnostic: Specializes in diagnostic instrumentation, reagents, software and related products for the clinical laboratory.

Grifols is a global healthcare company headquartered in Barcelona, Spain. The company produces and markets plasmaderived medicines as well as hospital pharmacy products, compounded IV solutions, and in vitro diagnostic products for clinical laboratories. Grifols employs more than 8,000 people in the U.S. and 11,200 people worldwide, and its products are sold in more than 90 countries.

A Legacy of Innovation At Grifols, a history of innovation defines our modern-day approach to medicine. More than 70 years ago, a Spanish hematologist named Dr. Jose Antonio Grifols Roig pursued a line of research

Products Albumin (Human), marketed as Albutein® 5%, Albutein® 25% and Plasbumin® _ 5 and Plasbumin® _ 25 Alpha1-Proteinase Inhibitor (Human), marketed as Prolastin®-C Antihemophilic Factor/von Willebrand Factor Complex (Human), marketed as Alphanate® Antithrombin III (Human), marketed as Thrombate III ® Coagulation Factor IX (Human), marketed as AlphaNine® SD

Edwin J. Cohn & Jose Antonio Grifols at the 4th International Congress of Blood Transfusion, Lisbon 1951.

Factor IX Complex, marketed as Profilnine® SD Hyperimmune Globulin Therapy Products, marketed as Hypermunes™: • Rabies Immune Globulin (Human) marketed as HyperRAB® S/D

that would set the stage for contemporary use of human plasma to treat disease. Together with his sons, he founded Laboratorios Grifols in 1940.

Among their pioneering achievements, they

obtained a patent in Spain for the process of plasma lyophilization, or freeze-drying of human plasma, along with the devices needed to inject plasma into patients who required its therapeutic properties.

Shortly thereafter, in 1951, Dr. Jose Antonio Grifols Lucas published the first large-scale clinical data describing the plasmapheresis technique of extracting plasma from donors while returning their red blood cells. Combined with the work of Edwin Cohn, Grifols paved the way for the birth of the plasma fractionation industry as we know it today.

Expanding to Meet the Demand From these auspicious beginnings, Grifols has evolved into an industry leader in the collection, manufacture and marketing of plasma-derived therapies. Through recent acquisitions, Grifols is now the third largest global producer of plasma-derived medicines.

Grifols operates the world’s largest plasma collection platform, with 150 source plasma donation centers across the U.S. Grifols currently has the world’s highest plasma protein fractionation capacity of more than 8 million liters of plasma per year. To accommodate the growing global demand for plasmaderived medicines, Grifols is significantly expanding its three manufacturing sites in Clayton, NC, Los Angeles, CA, and Barcelona, Spain – the company’s global headquarters. The expansions include a new, 185,000-square-foot fractionation facility in Clayton and a new facility in Los Angeles dedicated to the production of immune globulin therapies. The new manufacturing facilities will increase the company’s capacity to fractionate plasma to 12 million liters by 2015.

In addition, this year, Grifols opened a new, state-of-the-art plasma testing laboratory in San Marcos, TX, where every plasma donation undergoes rigorous scientific analysis prior to being approved for use in manufacturing. The 72,000-square-foot-facility houses the latest technology for conducting sophisticated viral testing, including transcription mediated amplification to rapidly detect minute levels of viral material within plasma samples. The San Marcos laboratory, together with an existing plasma testing laboratory in Austin, will analyze millions of plasma samples annually.

Grifols is firmly committed to giving patients and healthcare providers broad access to our products. As Grifols grows, it continues to pursue its mission of improving the health and well-being of people around the world.

• Tetanus Immune Globulin (Human) marketed as HyperTET® S/D • Rho (D) Immune Globulin (Human) marketed as HyperRHO® S/D • Hepatitis B Immune Globulin (Human) marketed as HyperHEP B® S/D Immune Globulin Intravenous (Human) or IVIG Immune Globulin Injection (Human) Gri-fill® System 3.0 for compounding sterile preparations Misterium®: modular clean room solution Grifols-SencorpWhite inventory management system solutions Phocus® Rx: remote pharmacist validation system for compounding IV preparations Grifols Triturus® Fully Automated EIA Analyzer Interlab G26 Clinical Agarose Gel Electrophoresis Systems

Flebogamma® DIF manufacturing plant in Barcelona, Spain, designed by Grifols Engineering.

Diesse Ves-Matic ESR (Sed Rate) Systems A full line of Diagnostic Reagents and Complete Solutions for the Clinical Laboratory

CO23-0612

22

Corporate Profile 2012

Special Advertising Section Pharmacy Practice News

ICU Medical, Inc. ICU Medical connects patients and caregivers through safe, life-saving, life-enhancing medical devices, providing clinicians around the world with innovative and cost-effective patient care solutions for unmet clinical needs. Since the 1970s, the unsafe handling of hazardous drugs used to treat many forms of cancer has been recognized as a significant health hazard to healthcare workers, including oncology pharmacists. In response to these well-documented risks, ICU Medical has developed the ChemoClaveTM system, the world’s only needlefree closed system transfer device (CSTD) for the safe handling of hazardous drugs.

The ChemoClave System ICU Medical’s ChemoClave system is designed to keep clinicians safe from dangerous exposure to hazardous drugs and features a variety of needlefree vial access devices, bag spikes, as well as primary and administration sets that can be configured to meet individual clinical needs. These devices work together to create and maintain

tem with automatic self-sealing technology that requires no cumbersome component assembly.

This intuitive system meets NIOSH and ASHP guidelines, and can help ensure safe handling compliance throughout the entire hazardous drug handling process.

Less Waste, Lower Cost

AT A GLANCE Address ICU Medical, Inc. 951 Calle Amanecer San Clemente, CA 92673 Phone: (866) 829-9025 Fax: (949) 366-2183 Web site: www.icumed.com

As economic pressures increase for healthcare facilities, the need to drive clinical and economic efficiencies is more critical than ever.

The ChemoClave system can help facilities sigChairman of the Board, nificantly reduce biohazardous waste and lower President and Chief their implementation costs compared to other Executive Officer commercially available CSTDs. Reducing biohazardous waste helps lower the chance of George A. Lopez, MD environmental exposure to hazardous drugs and decreases hazardous waste removal costs.

A recent study looked at the costs associated with implementing various CSTD systems throughout the clinical delivery continuum, including the preparation, transportation, administration, and disposal of hazardous drugs. Real cost savings was estimated to be as much as $307,000 a year with the ChemoClave System for a single high-volume cancer facility as compared to other CSTD systems. Another study that analyzed costs of available CSTDs estimated that using the ChemoClave System could save a facility between $57.50 and $112.50 for every 100 chemotherapy bags administered.

Commitment to the Safety of Oncology Pharmacists Treating cancer patients takes compassion. It shouldn’t take your life. With limited federal regulation for devices that reduce exposure to hazardous drugs, ICU Medical has taken responsibility to increase clinical awareness of the dangers of exposure to these chemicals and improve safety throughout the oncology drug handling process. ICU Medical is committed to providing easy-to-use needlefree solutions that generate less biohazardous waste and lower costs, while helping keep clinicians and patients safe.

Only ICU Medical gives you a simple, safe and secure needlefree closed system transfer device to help enhance healthcare worker safety and comply with OSHA, NIOSH, ASHP, ISOPP, ONS, APHON and USP <797>. For more information on how to keep you and your patients safe, visit us at www.icumed.com or call 1-866-829-9025. a mechanically and microbiologically closed system throughout the preparation, transportation, administration, and disposal of hazardous drugs. At no point in the process are clinicians, patients, or the environment exposed to hazardous chemicals.

Needlefree ICU Medical is committed to helping facilities adhere to needlefree policies. The needlefree ChemoClave system eliminates the risk of hazardous needlestick injuries during the oncology drug safe handling process. ChemoClave system features a passive, self-sealing technology that automatically returns each device to the closed position when disconnected, whether intentionally or by accident. As a closed system, ChemoClave features permanently bonded connections that eliminate add-on components and the potential for unsafe disconnect points.

Easy to Use Because ChemoClave is so easy to use, it reduces opportunities for misuse or malfunction while increasing compliance with safe handling best practices. ICU Medical developed the ChemoClave sys-

Special Advertising Section Pharmacy Practice News

Corporate Profile 2012

23

Medi-Dose, Inc./EPS, Inc. AT A GLANCE

Pioneers of unit-dose packaging, The Medi-Dose® Group constantly responds to pharmacy needs with innovative solid and liquid, oral unit-dose packaging products and a wide range of flexible, cost-effective IV, filtration, pharmacy and nursing accessories.

EPS, Inc.: A Focus on IV Medications

EPS® (Extemporaneous Packaging Systems), Inc., a companion company to Medi-Dose, Inc., was founded in 1977. Today, EPS manufactures and markets liquid unit-dose packaging supplies and IV addiAddress tive disposables for the preparation and dispensing of IV medications.

70 Industrial Drive Other EPS products include male/female Luer-lock closures, injection Ivyland, PA 18974 ports, trays and totes, tapes and labels, UV inhibitant bags and resealPhone: (800) 523-8966 able bags, IV software and high-alert medication identification bands.

Fax: (800) 323-8966 Like Medi-Dose, the EPS TampAlerT® system for liquids offers E-mail: info@medi-dose.com The Medi-Dose Group has always had deep tamper evidence. “The premier advantage of TampAlerT is its Web site: www.medi-dose.com roots—family roots. Medi-Dose began as a small tamper-evident seal,” Robert Braverman said. “Ten minutes after you dispense your liquid and screw family business in 1971, when Milton Braverman, Products a former pharmaceutical company territory manthe TampAlerT cap on the vial, the ager, formed his own company. He was acutely seal is in place. Heat tunnels and Medi-Dose® (Solid) and TampAlerT® (Liquid) Oral accessory sealing equipment are not aware of the requirements of hospital pharmacy.

Unit-Dose Packaging His sons, Robert and Mark, continue the tradition necessary. TampAlerT is tamper evidence with a twist of the wrist!” for The Medi-Dose Group.

Medi-Cup® PLUS packaging for The Bravermans carved a niche for the comThe company’s IV accessories also extended beyond-use dating pany—initially with solid oral unit-dose packagare highly successful. “We see them ® MILT by Medi-Dose unit-dose and ing.

Although the concept of unit dose is familiar as natural advancements of the inibar-coding software today, launching the idea was one of the biggest tial Medi-Dose system. In essence, LiquiDose® labeling, IV additive and Milt 3.0 software.

IV dispensing is a highly specialized problems the new company faced. “We were filtration products form of unit dose,” he added. “It’s the one of the pioneers, the innovators promoting Nultraviolet® ultraviolet light inhibiunit dose in hospitals,” Robsame idea—preparing and admintant bags ert Braverman recalled. “Due istering predetermined amounts of Steri-Dropper sterile ophthalmic medication for one regular dose or in part to Medi-Dose’s educadropper bottles tional efforts, pharmacists and application.”

Although all of the products connurses accepted the validity of High Alert and I.V. Line Tracing Labels tinue to meet with gratifying, wideunit dose.”

Medi-Dose is constantly spread acceptance, both Medi-Dose Resealable bags, bottles and other and EPS remain highly motivatresponding to pharmacy packpharmacy supplies and disposables ed. “We’re always looking for new aging needs. Providing stability, ultraviolet (UV) light inhibition, products and developing innovaPharmacists’ input has made Medi-Dose the ideal tive, cost-effective ways to help easy opening and tamper evimanual, solid oral unit-dose packaging system. dence have always been parapharmacists, always with an eye mount concerns regarding prepackaging. Using toward reducing the potential for medication error,” noted Mr. BraverMedi-Dose, a pharmacist can package a medication and store man. “One of our newest products it for up to one year without loss meeting these criteria is our line of potency due to UV light transof IV and High Alert Line Tracing mission or moisture permeation.

Labels which makes it easy to label Hospitals can install the Mediand trace IV lines for any medicaDose solid oral unit-dose system tion in any setting (hospital, home for about $700; this includes all or clinic). Pharmacy simply places the supplies for 5,000 doses of the entire label on an IV infusion medication, as well as software container. When the medication is EPS’s innovative Line Tracing Label with a unique three-part piggyback for complete medication and administered at the bedside, nursdesign provides safe and economical protection for IV lines. bar-coding identification. Total ing applies one line label to each end of the tubing. This facilitates easy line traces, improves accusolid and liquid oral systems can be set up for less than $1,000. racy and helps minimize IV line confusion.” He added that 10 preMILT® by Medi-Dose Software printed labels as well as customizable Line Tracing Labels (when With bar coding increasingly important to pharmacy practice, used with the MILT 3.0 software) are immediately available.

Medi-Dose designed its widely used MILT® by Medi-Dose software “All our IV High Alert and Line Tracing Labels reduce the potential for error, minimize liability exposure and save lives—all for an extreme(Medi-Dose Information Labeling Technology, named for the company’s founder). “My father wanted bar coding on medication packagly affordable price,” Mr. Braverman said. ing early on, to minimize the potential for medication error,” Robert Mark D. Braverman, director of operations, is responsible for Braverman said. “So, we’ve been constantly improving our programs the company’s extensive computer network. He coordinates all purchasing activities, both domestic and international. Mark and to meet this vital pharmacy challenge and need.”

Robert are aggressively bringing an expanded line of economically MILT 3.0 by Medi-Dose not only has sophisticated one- and twodimensional bar-coding technology to include lot numbers, beyondpriced, generic alternatives to expensive brands of plastic products use dates and National Drug Codes (NDC) on one bar code; it also to the company’s customers. includes an upgradable NDC database, directly from the FDA. PharRobert Braverman noted, “We’ve come a long way from being macists can simply type or scan in the NDC number, and MILT by a small family business; we still have remained as attentive and responsive to pharmacy needs as we were more than 30 years ago.

Medi-Dose will supply the pertinent information. The pharmacist can map this information to designated fields, reducing the risk for error.

Now we have the ability and the products to respond to pharmacists’ needs all over the MILT by Medi-Dose also contains field-locking capability for extra world—and we do.” security; enhanced formatting for quick medication identification; support for syringe, ampule and IV Line Tracing labeling; customized work flow and comprehensive logs and reports; as well as laser, inkjet and thermal printer capabilities.

24

Corporate Profile 2012

Special Advertising Section Pharmacy Practice News

PharMEDium Services PharMEDium is the leading outsourced pharmacy provider, rigorously ensuring the accuracy and sterility of all your customized sterile compounded preparations.

The company has grown into a nationwide network of state-licensed and federally registered compounding centers providing trusted solutions to more than 2,000 hospitals throughout the United States. Managed by licensed pharmacists and staffed by certified technicians, PharMEDium complies with all appropriate state laws and federal regulations, including requirements from the United States Pharmacopeia Chapter <797> and the Drug Enforcement Administration.

Admixtures for All Areas of Your Hospital PharMEDium can help. With proven admixture services for all areas of the hospital, PharMEDium can significantly reduce the time and effort required to produce high-quality compounded preparations.

Your pharmacy will run smoothly, your admixtures will stay compliant with current and future regulations, and you’ll have more time to focus on what you do best: taking care of your patients.

Supported specialties include: • Pain management PCAs and epidurals; labor and delivery, nerve block and local anesthetics, ICU, OR anesthesia syringe preparations; electrolyte solutions; antibiotics; antiemetics, cardiovascular/cardioplegia; renal replacement solutions; intrathecal preparations.

• PharMEDium anesthesia custom syringe preparations, featuring rigorous sterility controls, accurate preparation. These products improve drug-name recognition in critical situations, thanks to labels with American Society of Anesthesiologists–endorsed ASTM color-coding by drug class.

At PharMEDium, we understand that accuracy must begin long before a compounded preparation enters the OR. That’s why we developed a process of 200% inspection along with a highly specialized system that uses automated bar-code verification to ensure that the right drug in the right concentration is present in each syringe and is labeled correctly, every time. PharMEDium’s tamper-evident packaging enhances patient care by reducing the potential for diversion and waste.

Special Advertising Section Pharmacy Practice News

PharMEDium OR anesthesia syringe preparations, in an array of requested concentrations, include: • Opioids: fentanyl, morphine PF, hydromorphone, remifentanil • Vasopressors: phenylephrine, ephedrine, epinephrine • Sedatives: midazolam, lorazepam • Blockade agents: succinylcholine, rocuronium, vecuronium, cisatracurium • Reversal agents: neostigmine • Anticholinergics: glycopyrrolate, atropine • Induction agents: ketamine, propofol • Local anesthetics: bupivacaine, ropivacaine, lidocaine, lidocaine PF • Antibiotics: cefazolin • β-blockers: labetolol, esmolol

Industry-Leading Label Design

AT A GLANCE Address Two Conway Park 150 N Field Drive, Suite 350 Lake Forest, IL 60045 Phone: (800) 523-7749 Web site: www.pharmedium.com

Services Pain management PCAs and epidurals; labor and delivery, nerve block and local anesthetics, OR anesthesia syringe preparations; electrolyte solutions; antibiotics; antiemetics, cardiovascular/cardioplegia; renal replacement solutions; total parenteral nutrition; intrathecal preparations.

The admixtures you receive from PharMEDium feature easy-to-read labels designed to help reduce errors and facilitate proper administration: • Dual drug-name bands and vertical drug-name strip along graduation marks ensure that the drug name is visible in any position, including along the graduation marks during the administration process.

• Easy-to-see “TALL man” lettering allows for instant drug recognition • Drug concentration and total dose are listed, clearly indicating the precise amount of active drug contained in the admixture • Lot number and expiration date are prominent • Bar codes meet GS1 standards and FDA regulations for drug identification • CII nomenclature indicates a scheduled substance • Enhanced safety messaging for correct infusion

e222: The Only Drug Order Form Officially Endorsed by Trees Paperless. Effortless. Costs less. Only from PharMEDium.

Enjoy the benefits of PharMEDium even faster. An electronic version of DEA Form 222 for Schedule II Controlled Substances (e222) can now be filled out and submitted electronically at www.pharmedium. com. You can reduce the time you spend filling out orders from minutes to seconds! PharMEDium is the only outsourced compounder to offer this service!

To learn more about PharMEDium, please visit the Web site at www.p har m ediu m.com or call u s at (800) 523-7749.

Corporate Profile 2012

25

Pharmacy Practice News AT A GLANCE Address 545 W. 45th Street, 8th Floor New York, NY 10036 Phone: (212) 957-5300 Fax: (212) 957-7230 Web sites: www.mcmahonmed.com www.pharmacypracticenews.com www.cmezone.com

Launched more than 30 years ago, Pharmacy Practice Newss has become the best-read newspaper in its field, according to a syndicated, independent readership survey by Kantar Media.

According to the survey, Pharmacy Practice Newss achieved a No. 1 ranking in at least five major readership categories* among staff pharmacists, pharmacy directors and other key health-system personnel.

Products

combating cardiac drug poisonings.

Educational Reviews One of the core editorial features of Pharmacy Practice News is our monthly educational reviews. Written by authorities in a given treatment area, the reviews are comprehensive summaries of state-of-theart thinking on specific disease states and practice areas. Topics this year included hazardous drug handling, medication safety systems in the ICU, emerging therapies in the treatment of metastatic melanoma, and management of anemia in patients with chronic kidney disease. Many of these educational reviews are featured in Pharmacy Practice News Special Edition, our annual print compendium that mails in October.

Web Site Initiatives

Medical newsmagazines, custom medical publications, educational reviews, educational and instructional pocket guides, special editions.

Our Mission

Each month, all of our print articles are posted to pharmacyThe mission of Pharmacy Practice Newss is twopracticenews.com and can be shared via easy-to-access links to fold: to provide health-system pharmacists with Facebook, Twitter and other social and business networking sites. the information they need to provide high-quality Web-exclusive content, such as breaking news and expanded coverpatient care, and to help them age of stories that appear in the magazine, also demonstrate the value of that care are featured.

Employees to colleagues and administrators.

Our monthly opt-in e-newsletter, previewing 69 To achieve these goals, our edicover stories and other featured content, contors follow developments in both tinues to grow and is sent about a week before Publisher, CEO and research and hospital practice. the print issue mails. We also are continuing to pharmacypracticenews.com Managing Partner post podcast interviews with our advisory board Most of our coverage comes from Raymond E. McMahon members, who comment on articles and issues attending meetings convened by the major pharmacy groups, such as the American of interest to health-system pharmacists.

President, Partner Society of Health-System Pharmacists. But we also Van Velle Parent Company attend smaller, more focused conferences to keep Pharmacy Practice News’’ leading position in readership did not our readers abreast of specialty care. For example, Pharmacy Practice News the magazine continues to step up its coverage occur in a vacuum: The magazine is part of the McMahon PublishPublication Director ing family of specialty newspapers, many of which are the No. 1 read of the Hematology/Oncology Pharmacy Association’s annual meeting. We also cover the annual publications in their fields. Anesthesiology News, General Surgery Dave Kaplan News and Gastroenterology and Endoscopy News, for example, are meeting of the Society of Critical Care Medicine (SCCM) and the UnSummit for Bedside Barcoding. perennial favorites. Additional titles launched within the past five Editorial Director years, such as Clinical Oncology News and Pain Medicine News, conDavid Bronstein Peer-to-Peer Content tinue their impressive growth in market share and readership.

The magazine also welcomes contributions Senior Editor Supplements and Projects from readers in an effort to facilitate a peer-toSarah Tilyou peer exchange of best practices in health-system All of our publications include educational supplements such as Special pharmacy. Contributions can be in the form of Reports and Literature Reviews—custom-written monographs bound Production Manager inside the newspapers. These supplements, produced by the Special Practice Pearls, such as the one submitted by Marty Barbieri the AIDS Healthcare Foundation, on preventing Projects division of McMahon Publishing, can be based on symposium adverse drug events in patients with HIV/AIDS coverage, interviews with experts, recently published research and Art Director (p. 34). We also so forth, and often are CME/CE accredited. Other Frank Tagarello feature regular offerings from the company’s Special Projects division contributions from include wall charts and pocket guides—often based thought leaders in on our educational reviews—that serve as on-the-spot pharmacy, includinstructional tools for health care providers. ing Ernie Anderson Jr., MS, RPh, who Taken together, all of these educational initiatives authors the monthly “Leadership in underscore our company’s mission: to be a full-service Action” column (p. 31), and Bonnie publishing company for a full-service profession.

Kirschenbaum, MS, FASHP, who pens the bimonthly “Reimbursement Mat* No. 1 ranking in: average ters” column (p. 33). issue readers, directors This year, we also continue to fea(Table 115); average page ture our special “Spotlight” sections exposures, directors (Table focusing on important clinical and 115); high readers, total operational areas of pharmacy prachealth-system pharmacy tice. Our latest Spotlight theme, on (Table 217); average page Medication Safety, appeared in the exposures, total healthApril 2012 issue and featured articles system pharmacy (Table on the ISMP’s new International Medi117); high readers, staff cation Safety Self-Assessment Tool (Table 216). 2010 Pharmacy for Oncology; ISMP’s “Year in Review” Readership Study, Kantar educational review on medication Media. safety; and the latest strategies for

26

Corporate Profile 2012

Special Advertising Section Pharmacy Practice News